BACKGROUND： Previous studies have demonstrated that brain-derived neurotrophic factor （BDNF） promotes neural differentiation. However, the mechanisms involved in cell cycle-related protein regulation, which highly ...BACKGROUND： Previous studies have demonstrated that brain-derived neurotrophic factor （BDNF） promotes neural differentiation. However, the mechanisms involved in cell cycle-related protein regulation, which highly correlates to neural proliferation and apoptosis, remain poorly understood. OBJECTIVE： To investigate the effects of various concentrations of BDNF on cycle-related protein mRNA expression in induce-differentiated SH-SY5Y cells in vitro prior to and following G2 phase, and to analyze the neuroprotective effects of BDNF. DESIGN, TIME AND SETTING： A comparison, observational study, based on cell biology, was performed at the Department of Biochemistry, Medical College of Tongji University, from March 2005 to October 2006. MATERIALS： SH-SY5Y cells were provided by Shanghai Institute of Cytology, Chinese Academy of Science; BDNF by Alomone Labs, Israel; all-trans retinoic acid （ATRA） by Sigma-Aldrich, USA. METHODS： SH-SY5Y cells were randomly divided into three groups： blank control [cells were treated in Insulin-Transferrin-Selenium （ITS） solution for 7 days], ATRA （cells were treated with ITS solution containing 10 μmol/L ATRA for 7 days）, and BDNF （cells were treated identical to the ATRA group for 5 days, and then respectively treated in ITS solution containing 1, 10, and 100 μg/L BDNF for 2 days）. The experiment was repeated three times for each group. MAIN OUTCOME MEASURES： mRNA expression levels of cyclin A1, B1, B2, cyclin-dependent kinase 1, and 5 were detected using quantitative real-time RT-PCR; percentage of cells in G1, S, and G2 phases were detected using fluorescence-activated cell sorting. RESULTS： mRNA expression levels of cyclin A1 in the high-dose BDNF group was significantly less than the ATRA group （P 〈 0.05）.mRNA expression levels of cyclin B1 was significantly less in the different BDNF concentration groups compared with the control and ATRA groups （P 〈 0.05 or P 〈 0.01）. mRNA expression levels of cyclin B2 and cyclin-dependent kinas展开更多
目的探讨肾癌组织中肿瘤细胞周期相关蛋白(cell-cycle-related and expression-elevated protein in tumor,CREPT)的表达与临床病理特征和生存率的关系。方法纳入90例于2014至2016年间在北京大学人民医院接受了根治性肾切除术并经组织...目的探讨肾癌组织中肿瘤细胞周期相关蛋白(cell-cycle-related and expression-elevated protein in tumor,CREPT)的表达与临床病理特征和生存率的关系。方法纳入90例于2014至2016年间在北京大学人民医院接受了根治性肾切除术并经组织学证实的肾癌患者,运用免疫组织化学方法检测这些患者的癌组织和癌旁组织中CREPT的表达,并结合临床病理资料分析CREPT表达水平与患者TNM分期和Fuhrman分级的关系。通过Kaplan-Meier生存分析及多因素COX回归分析CREPT表达与预后的关系。结果46.7%(42/90)的患者癌组织中CREPT表达为高水平,而在癌旁组织中所有患者CREPT表达均为低水平,组间比较差异有统计学意义(P<0.05)。CREPT的表达水平与TNM分期(P=0.001)和Fuhrman分级(P<0.001)有关联,但与性别(P=0.149)、年龄(P=0.605)、肿瘤大小(P=0.673)和组织学类型(P=0.756)无关。截至2018年12月,有85例患者完成随访。Kaplan-Meier分析显示,CREPT高表达患者总生存时间和无瘤生存时间均低于CREPT低表达患者,差异有统计学意义(P<0.05)。多因素COX回归分析显示,患者总生存时间及无瘤生存时间与CREPT的表达水平有关(P<0.05)。结论CREPT在肾癌组织中呈高表达,表达水平与临床分期、分级以及患者预后密切相关。展开更多
文摘BACKGROUND： Previous studies have demonstrated that brain-derived neurotrophic factor （BDNF） promotes neural differentiation. However, the mechanisms involved in cell cycle-related protein regulation, which highly correlates to neural proliferation and apoptosis, remain poorly understood. OBJECTIVE： To investigate the effects of various concentrations of BDNF on cycle-related protein mRNA expression in induce-differentiated SH-SY5Y cells in vitro prior to and following G2 phase, and to analyze the neuroprotective effects of BDNF. DESIGN, TIME AND SETTING： A comparison, observational study, based on cell biology, was performed at the Department of Biochemistry, Medical College of Tongji University, from March 2005 to October 2006. MATERIALS： SH-SY5Y cells were provided by Shanghai Institute of Cytology, Chinese Academy of Science; BDNF by Alomone Labs, Israel; all-trans retinoic acid （ATRA） by Sigma-Aldrich, USA. METHODS： SH-SY5Y cells were randomly divided into three groups： blank control [cells were treated in Insulin-Transferrin-Selenium （ITS） solution for 7 days], ATRA （cells were treated with ITS solution containing 10 μmol/L ATRA for 7 days）, and BDNF （cells were treated identical to the ATRA group for 5 days, and then respectively treated in ITS solution containing 1, 10, and 100 μg/L BDNF for 2 days）. The experiment was repeated three times for each group. MAIN OUTCOME MEASURES： mRNA expression levels of cyclin A1, B1, B2, cyclin-dependent kinase 1, and 5 were detected using quantitative real-time RT-PCR; percentage of cells in G1, S, and G2 phases were detected using fluorescence-activated cell sorting. RESULTS： mRNA expression levels of cyclin A1 in the high-dose BDNF group was significantly less than the ATRA group （P 〈 0.05）.mRNA expression levels of cyclin B1 was significantly less in the different BDNF concentration groups compared with the control and ATRA groups （P 〈 0.05 or P 〈 0.01）. mRNA expression levels of cyclin B2 and cyclin-dependent kinas
文摘目的探讨肾癌组织中肿瘤细胞周期相关蛋白(cell-cycle-related and expression-elevated protein in tumor,CREPT)的表达与临床病理特征和生存率的关系。方法纳入90例于2014至2016年间在北京大学人民医院接受了根治性肾切除术并经组织学证实的肾癌患者,运用免疫组织化学方法检测这些患者的癌组织和癌旁组织中CREPT的表达,并结合临床病理资料分析CREPT表达水平与患者TNM分期和Fuhrman分级的关系。通过Kaplan-Meier生存分析及多因素COX回归分析CREPT表达与预后的关系。结果46.7%(42/90)的患者癌组织中CREPT表达为高水平,而在癌旁组织中所有患者CREPT表达均为低水平,组间比较差异有统计学意义(P<0.05)。CREPT的表达水平与TNM分期(P=0.001)和Fuhrman分级(P<0.001)有关联,但与性别(P=0.149)、年龄(P=0.605)、肿瘤大小(P=0.673)和组织学类型(P=0.756)无关。截至2018年12月,有85例患者完成随访。Kaplan-Meier分析显示,CREPT高表达患者总生存时间和无瘤生存时间均低于CREPT低表达患者,差异有统计学意义(P<0.05)。多因素COX回归分析显示,患者总生存时间及无瘤生存时间与CREPT的表达水平有关(P<0.05)。结论CREPT在肾癌组织中呈高表达,表达水平与临床分期、分级以及患者预后密切相关。
